Source: CureToday articles
The FDA’s Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population.
Recent Content
- NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma
- FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns
- FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma
- Blenrep fails to receive ODAC support for multiple myeloma use
- Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma
- Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
- Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis
- Patient Perspective: Diagnosis of Multiple Myeloma
- Treatment of Multiple Myeloma
- Introduction and Overview of Multiple Myeloma